Literature DB >> 29611209

Intensity of surveillance for hepatocellular carcinoma determines survival in patients at risk in a hepatitis B-endemic area.

H Y Kim1, J Y Nam2, J-H Lee2, H A Lee3, Y Chang2, H Y Lee2, H Cho2, D H Lee4, Y Y Cho2, E J Cho2, S J Yu2, J M Lee4, Y J Kim2, J-H Yoon2.   

Abstract

BACKGROUND: Data are insufficient regarding the survival benefit of surveillance for hepatocellular carcinoma (HCC). AIM: To investigate the effectiveness of HCC surveillance in a hepatitis B-endemic population.
METHODS: This retrospective cohort study included 1402 consecutive patients who were newly diagnosed with HCC between 2005 and 2012 at a single tertiary hospital in Korea. The primary endpoint was overall survival. Lead-time and length-time biases were adjusted (sojourn time = 140 days) and sensitivity analyses were performed.
RESULTS: The most common aetiology was hepatitis B (80.4%). Cirrhosis was present in 78.2%. HCC was diagnosed during regular surveillance (defined as mean interval of ultrasonography <8 months, n = 834), irregular surveillance (n = 104) or nonsurveillance (n = 464). Patients in the regular surveillance group were diagnosed at earlier stages ([very] early stage, 64.4%) than the irregular surveillance (40.4%) or nonsurveillance (26.9%) groups and had more chance for curative treatments (52.4%) than the irregular surveillance (39.4%) or nonsurveillance (23.3%) groups (all P < 0.001). Mortality risk was significantly lower in the regular surveillance group (adjusted hazard ratio [aHR], 0.69; 95% [CI], 0.57-0.83) but not in the irregular surveillance group (aHR, 0.94; 95% CI, 0.69-1.28) compared with the nonsurveillance group after adjusting for confounding factors and lead-time. When the subjects were restricted to cirrhotic patients or Child-Pugh class A/B patients, similar results were obtained for mortality risk reduction between groups.
CONCLUSIONS: HCC surveillance was associated with longer survival owing to earlier diagnosis and curative treatment. Survival advantage was significant with regular surveillance but not with irregular surveillance.
© 2018 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2018        PMID: 29611209     DOI: 10.1111/apt.14623

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  6 in total

1.  Surveillance for Hepatocellular Carcinoma: Does the Place Where Ultrasound Is Performed Impact Its Effectiveness?

Authors:  Federico Piñero; Fernando Rubinstein; Sebastián Marciano; Nora Fernández; Jorge Silva; Yanina Zambelo; Margarita Anders; Alina Zerega; Ezequiel Ridruejo; Carlos Miguez; Beatriz Ameigeiras; Claudia D'Amico; Luis Gaite; Carla Bermúdez; Carlos Rosales; Gustavo Romero; Lucas McCormack; Virginia Reggiardo; Luis Colombato; Adrián Gadano; Marcelo Silva
Journal:  Dig Dis Sci       Date:  2018-12-03       Impact factor: 3.199

Review 2.  KASL clinical practice guidelines for management of chronic hepatitis B.

Authors: 
Journal:  Clin Mol Hepatol       Date:  2019-06-12

Review 3.  Optimal Modalities for HCC Surveillance in a High-Incidence Region.

Authors:  Young Chang; Jeong-Hoon Lee
Journal:  Clin Liver Dis (Hoboken)       Date:  2021-01-13

4.  A correlation analysis of the serum hepcidin concentrations and viral loads in HCV-infected patients.

Authors:  Rongqi Wang; Suxian Zhao; Jinghua Du; Jie Qiao; Wencong Li; Yuemin Nan
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

5.  Efficacy of microwave ablation versus radiofrequency ablation for hepatocellular carcinoma: a propensity score analysis.

Authors:  Kanehiko Suwa; Toshihito Seki; Kazunori Aoi; Masao Yamashina; Miki Murata; Noriyo Yamashiki; Akiyoshi Nishio; Masaaki Shimatani; Makoto Naganuma
Journal:  Abdom Radiol (NY)       Date:  2021-03-06

6.  Proteome Multimarker Panel for the Early Detection of Hepatocellular Carcinoma: Multicenter Derivation, Validation, and Comparison.

Authors:  Ju Yeon Kim; Jaenyeon Kim; Young-Suk Lim; Geum-Youn Gwak; Injoon Yeo; Yoseop Kim; Jihyeon Lee; Dongyoon Shin; Jeong-Hoon Lee; Youngsoo Kim
Journal:  ACS Omega       Date:  2022-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.